CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Keymed Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Keymed Biosciences Inc
18 Biotown Middle Road Building D2
Chengdu Tianfu International Biotown
CHENGDU, SIC  610219  China Ticker: 21622162
Business Summary
KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer BoChen 48 4/3/2021 4/23/2018
Chief Financial Officer, Company Secretary YanrongZhang 35 4/3/2021 9/1/2020
Senior Vice President, Executive Director ChangyuWang 57 4/3/2021 3/3/2021
9 additional Officers and Directors records available in full report.

Business Names
Business Name
2162
64Z

General Information
Number of Employees: 1,116 (As of 6/30/2024)
Outstanding Shares: 279,735,566 (As of 6/30/2024)
Stock Exchange: HKG


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024